MRK Stock: Insider Activity, Filings & Research
Drillr aggregates AI research, SEC filings, earnings signals and alt-data for MRK. 5 published articles.
Insider Activity
Over the trailing 90-day window, MRK recorded no open-market purchases or sales by insiders, resulting in net insider buying of $0. The insider sentiment score stands at 50/100, indicating a neutral stance with no cluster buying activity observed. The stock declined 3.5% over the three-month period, while institutional 13F positioning has remained mixed. The absence of insider accumulation, combined with neutral sentiment signals, suggests limited conviction from company leadership during this period.
Updated Jun 4, 2026 · based on SEC Form 4 filings · not investment advice
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 2, 2026 | BAKER DOUGLAS M JRdirector | Grant | 1,853 | — |
| Jun 2, 2026 | Rothman Pauldirector | Grant | 1,853 | — |
| Jun 2, 2026 | GLOCER THOMAS Hdirector | Grant | 1,853 | — |
| Jun 2, 2026 | RUSSO PATRICIA Fdirector | Grant | 1,853 | — |
| Jun 2, 2026 | Seidman Christine Edirector | Grant | 1,853 | — |
| Jun 2, 2026 | LAVIZZO-MOUREY RISA Jdirector | Grant | 1,853 | — |
| Jun 2, 2026 | THULIN INGE Gdirector | Grant | 1,853 | — |
| Jun 2, 2026 | Craig Pamela J.director | Grant | 1,853 | — |
| Jun 2, 2026 | Karsanbhai Surendralal Lancadirector | Grant | 1,853 | — |
| Jun 2, 2026 | Coe Mary Ellendirector | Grant | 1,853 | — |
| Jun 2, 2026 | Warden Kathy Jdirector | Grant | 1,853 | — |
| Jun 2, 2026 | Mayo Stephendirector | Grant | 1,853 | — |
| May 7, 2026 | Larson Betty Dofficer: EVP, Chief HR Officer | Grant | 7,954 | — |
| May 7, 2026 | Foard Brianofficer: EVP, Specialty, Pharma, & ID | Grant | 31,044 | $113.15 |
| May 7, 2026 | Li Dean Yofficer: Executive VP & President, MRL | Grant | 58,207 | $113.15 |
Source: MRK SEC Form 4 filings, latest Jun 2, 2026. For informational purposes only — not investment advice.
Research
LLY: $2.3B Ajax Buy Hedges Mounjaro Patent Cliff
Eli Lilly's $2.3 billion Ajax Therapeutics acquisition reveals a critical divergence in large-cap pharma M&A strategy that the market has mispriced. While Merck and Pfizer scramble to replace patent cliff revenue with expensive blockbuster acquisitions, Lilly is buying rare-disease optionality from a position of GLP-1 strength. Long LLY versus short MRK/PFE targets 8-12% relative return over six months as earnings reveal the cost of desperate dealmaking.
LLYPFEBMYPharma Tariffs: Buy LLY & AMGN, Sell PFE & MRK — Here's Why
Trump policies eroding Europe's pharma lead via tariffs favor US manufacturing-heavy Eli Lilly and Amgen, with strong growth and margins, while Pfizer and Merck's global chains invite cost squeezes. J&J and AbbVie sit in the middle with diversification. Rank: Buy LLY/AMGN, sell PFE/MRK.
LLYAMGNABBVTrump 100% Pharma Tariffs: PFE and MRK Face $200M Hit While LLY Gains 25%
Trump's proposed 100% pharma tariffs and China's biotech surge, per April 11 CNBC, threaten Europe's manufacturing edge, hiking costs for PFE (-2.8% 1M) and MRK (-5.1% 1M) while LLY's US focus drives 25% 2026 growth. Supply chain filings flag $100-200M hits; investors should fade exposed names, buy domestic leaders. Next catalysts: Earnings tariff disclosures and China trade flows.
PFELLYTMOPharma Tariffs: LLY and AMGN Win While PFE and MRK Face Margin Squeeze
Trump's pharma import tariffs shield U.S.-focused drugmakers like Eli Lilly and Amgen from cost hikes while pressuring import-reliant Pfizer and Merck. Analysis ranks six majors by exposure, highlighting financials and guidance. Domestic winners eye margin expansion amid onshoring push.
LLYAMGNABBVPharma Tariffs: LLY, TMO, CVS Supply Chain Exposure Ranked by Risk
Trump's April 2 pharma tariff announcement highlights supply chain risks for LLY, TMO, and CVS, with SEC filings exposing China reliance. Stocks dipped mildly, but domestic manufacturing offers protection amid margin pressures.
PFELLYTMO
Track MRK with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free